Cholesterol-modifying strategies for Alzheimer’s disease

References

• Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261(5123), 921–923 (1993).
   PubMed Web of Science ®Google Scholar
• Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet342(8873), 697–699 (1993).
   PubMed Web of Science ®Google Scholar
• Sparks DL, Hunsaker JC 3rd, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer’s disease. Neurobiol. Aging11(6), 601–607 (1990).
   PubMed Web of Science ®Google Scholar
• Poirier J. Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer’s disease. Alzheimers Dement.4(1 Suppl 1), S91–S97 (2008).
   PubMed Web of Science ®Google Scholar
• Hooijmans CR, Kiliaan AJ. Fatty acids, lipid metabolism and Alzheimer pathology. Eur. J. Pharmacol.585(1), 176–196 (2008).
   PubMed Web of Science ®Google Scholar
• Carter CJ. Convergence of genes implicated in Alzheimer’s disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem. Int.50(1), 12–38 (2007).
   PubMed Web of Science ®Google Scholar
• Reiman EM, Chen K, Caselli RJ et al. Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer’s-affected brain regions. Neuroimage40(3), 1214–1221 (2008).
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Solomon A. Alzheimer’s disease – the ways of prevention. J. Nutr. Health Aging12(1), 89S–94S (2008).
   Web of Science ®Google Scholar
• Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer’s disease – epidemiological evidence. Acta Neurol. Scand. Suppl.185, 50–57 (2006).
   PubMedGoogle Scholar
• Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology57, 1447–1452 (2001).
   PubMed Web of Science ®Google Scholar
• Pappolla MA, Bryant-Thomas TK, Herbert D et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology61(2), 199–205 (2003).
   PubMed Web of Science ®Google Scholar
• Stewart R, White LR, Xue QL, Launer LJ. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu–Asia Aging Study. Arch. Neurol.64(1), 103–107 (2007).
   PubMed Web of Science ®Google Scholar
• Solomon A, Kåreholt I, Ngandu T et al. Serum cholesterol changes after midlife and late-life cognition: 21-year follow-up study. Neurology68(10), 751–756 (2007).
   PubMed Web of Science ®Google Scholar
• Laitinen M, Ngandu T, Rovio S, et al. Fat intake at midlife and risk of dementia and Alzheimer’s disease: a population-based study. Dement. Ger. Cogn. Disord.22, 99–107 (2006).
   PubMed Web of Science ®Google Scholar
• Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arteriosclr. Thromb. Vasc. Biol.24, 806–815 (2004).
   PubMed Web of Science ®Google Scholar
• Vance JE, Hayashi H, Karten B. Cholesterol homeostasis in neurons and glial cells. Semin. Cell Dev. Biol.16(2), 193–212 (2005).
   PubMed Web of Science ®Google Scholar
• Korade Z, Kenworthy AK. Lipid rafts, cholesterol, and the brain. Neuropharmacology55(8), 1265–1273 (2008).
   PubMed Web of Science ®Google Scholar
• Pfrieger FW. Cholesterol homeostasis and function in neurons of the central nervous system. Cell. Mol. Life Sci.60(6), 1158–1171 (2003).
   PubMed Web of Science ®Google Scholar
• Blain JF, Poirier J. Cholesterol homeostasis and the pathophysiology of Alzheimer’s disease. Expert Rev. Neurother.4(5), 823–829 (2004).
   PubMedGoogle Scholar
• Björkhem I. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J. Intern. Med.260(6), 493–508 (2006).
   PubMed Web of Science ®Google Scholar
• Vaya J, Schipper HM. Oxysterols, cholesterol homeostasis, and Alzheimer disease. J. Neurochem.102(6), 1727–1737 (2007).
   PubMed Web of Science ®Google Scholar
• Girouard H, Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J. Appl. Physiol.100(1), 328–335 (2006).
   PubMed Web of Science ®Google Scholar
• Sparks DL, Scheff SW, Hunsaker JC 3rd, Liu H, Landers T, Gross DR. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol.126(1), 88–94 (1994).
   PubMed Web of Science ®Google Scholar
• Refolo LM, Malester B, LaFrancois J et al. Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol. Dis.7, 321–331 (2000).
   PubMed Web of Science ®Google Scholar
• Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC. Diet-induced hypercholesterolemia enhances brain Aβ accumulation in transgenic mice. Neuroreport13, 455–459 (2002).
   PubMed Web of Science ®Google Scholar
• Wolf H, Hensel A, Arendt T, Kivipelto M, Winblad B, Gertz H-J. Serum lipids and hippocampal volume: the link to Alzheimer’s disease? Ann. Neurol.56, 745–749 (2004).
   PubMed Web of Science ®Google Scholar
• den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Serum lipids and hippocampal volume: the link to Alzheimer‘s disease? Ann. Neurol.57(5), 779–780 (2005).
   PubMed Web of Science ®Google Scholar
• Kuo YM, Emmerling MR, Bisgaier CL et al. Elevated low-density lipoprotein in Alzheimer’s disease correlates with brain Aβ 1–42 levels. Biochem. Biophys. Res. Commun.252(3), 711–715 (1998).
   PubMed Web of Science ®Google Scholar
• Caramelli P, Nitrini R, Maranhão R et al. Increased apolipoprotein B serum concentration in Alzheimer’s disease. Acta Neurol. Scand.100(1), 61–63 (1999).
   PubMed Web of Science ®Google Scholar
• Merched A, Xia Y, Visvikis S, Serot JM, Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease. Neurobiol. Aging21(1), 27–30 (2000).
   PubMed Web of Science ®Google Scholar
• Saczynski JS, White L, Peila RL, Rodriguez BL, Launer LJ. The relation between apolipoprotein A-I and dementia: the Honolulu–Asia aging study. Am. J. Epidemiol.165(9), 985–992 (2007).
   PubMed Web of Science ®Google Scholar
• Michikawa M. Role of cholesterol in amyloid cascade: cholesterol-dependent modulation of tau phosphorylation and mitochondrial function. Acta Neurol. Scand. Suppl.185, 21–26 (2006).
   PubMedGoogle Scholar
• Hartmann T, Kuchenbecker J, Grimm MO. Alzheimer’s disease: the lipid connection. J. Neurochem.103(Suppl. 1), 159–170 (2007).
   PubMed Web of Science ®Google Scholar
• Wood WG, Schroeder F, Igbavboa U, Avdulov NA, Chochina SV. Brain membrane cholesterol domains, aging and amyloid β-peptides. Neurobiol. Aging23(5), 685–694 (2002).
   PubMed Web of Science ®Google Scholar
• Hirsch-Reinshagen V, Burgess BL, Wellington CL. Why lipids are important for Alzheimer disease? Mol. Cell. Biochem. (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Grimm MO, Grimm HS, Hartmann T. Amyloid β as a regulator of lipid homeostasis. Trends Mol. Med.13(8), 337–344 (2007).
   PubMed Web of Science ®Google Scholar
• Xiong H, Callaghan D, Jones A et al. Cholesterol retention in Alzheimer’s brain is responsible for high β- and γ-secretase activities and Aβ production. Neurobiol. Dis.29(3), 422–437 (2008).
   PubMed Web of Science ®Google Scholar
• Grimm MO, Grimm HS, Pätzold AJ et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin. Nat. Cell Biol.7(11), 1118–1123 (2005).
   PubMed Web of Science ®Google Scholar
• Cordy JM, Hooper NM, Turner AJ. The involvement of lipid rafts in Alzheimer’s disease. Mol. Membr. Biol.23(1), 111–122 (2006).
   PubMed Web of Science ®Google Scholar
• Saavedra L, Mohamed A, Ma V, Kar S, de Chaves EP. Internalization of β-amyloid peptide by primary neurons in the absence of apolipoprotein E. J. Biol. Chem.282(49), 35722–35732 (2007).
   PubMed Web of Science ®Google Scholar
• Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: the cholesterol connection. Nat. Neurosci.6(4), 345–351 (2003).
   PubMed Web of Science ®Google Scholar
• Garcia-Ruiz C, Mari M, Colell A et al. Mitochondrial cholesterol in health and disease. Histol. Histopathol.24(1), 117–132 (2009).
   PubMed Web of Science ®Google Scholar
• Koschack J, Lütjohann D, Schmidt-Samoa C, Irle E. Serum 24S-hydroxycholesterol and hippocampal size in middle-aged normal individuals. Neurobiol. Aging (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Shafaati M, Solomon A, Kivipelto M, Björkhem I, Leoni V. Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders. Neurosci. Lett.425(2), 78–82 (2007).
   PubMed Web of Science ®Google Scholar
• Heverin M, Bogdanovic N, Lutjohann D et al. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer’s disease. J. Lipid Res.45, 186–193 (2004).
   PubMed Web of Science ®Google Scholar
• Bogdanovic N, Bretillon L, Lund EG et al. On the turnover of brain cholesterol in patients with Alzheimer’s disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci. Lett.314, 45–48 (2001).
   PubMed Web of Science ®Google Scholar
• Brown J, Theisler C, Silberman S et al. Differential expression of cholesterol hydroxylases in Alzheimer’s disease. J. Biol. Chem.279, 34674–34681 (2004).
   PubMed Web of Science ®Google Scholar
• Mateos L, Akterin S, Gil-Bea FJ et al. Activity-regulated cytoskeleton-associated protein in rodent brain is down-regulated by high fat diet in vivo and by 27-hydroxycholesterol in vitro. Brain Pathol.19(1), 69–80 (2009).
   PubMed Web of Science ®Google Scholar
• Sharma S, Prasanthi RPJ, Schommer E, Feist G, Ghribi O. Hypercholesterolemia-induced Aβ accumulation in rabbit brain is associated with alteration in IGF-1 signaling. Neurobiol. Dis.32(3), 426–432 (2008).
   PubMed Web of Science ®Google Scholar
• Alegret M, Silvestre JS. Pleiotropic effects of statins and related pharmacological experimental approaches. Methods Find. Exp. Clin. Pharmacol.28(9), 627–656 (2006).
   PubMed Web of Science ®Google Scholar
• Nieminen T, Kähönen M, Viiri LE, Grönroos P, Lehtimäki T. Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics9(10), 1475–1486 (2008).
   PubMed Web of Science ®Google Scholar
• Eckert GP, Kirsch C, Mueller WE. Differential effects of lovastatin treatment on brain cholesterol levels in normal and apoE-deficient mice. Neuroreport12(5), 883–887 (2001).
   PubMed Web of Science ®Google Scholar
• Refolo LM, Pappolla MA, LaFrancois J et al. A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol. Dis.8, 890–899 (2001).
   PubMed Web of Science ®Google Scholar
• Petanceska SS, DeRosa S, Olm V et al. Statin therapy for Alzheimer’s disease: will it work? J. Mol. Neurosci.19, 155–161 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson-Anuna LN, Eckert GP, Keller JH et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J. Pharmacol. Exp. Ther.312(2), 786–793 (2005).
   PubMed Web of Science ®Google Scholar
• Burns MP, Igbavboa U, Wang L, Wood WG, Duff K. Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice. Neuromolecular Med.8(3), 319–328 (2006).
   PubMed Web of Science ®Google Scholar
• Fassbender K, Simons M, Bergmann C et al. Simvastatin strongly reduces levels of Alzheimer’s disease β-amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc. Natl Acad. Sci. USA98, 5856–5861 (2001).
   PubMed Web of Science ®Google Scholar
• Lütjohann D, Stroick M, Bertsch T et al. High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids69(6), 431–438 (2004).
   PubMed Web of Science ®Google Scholar
• Thelen KM, Rentsch KM, Gutteck U et al. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J. Pharmacol. Exp. Ther.316(3), 1146–1152 (2006).
   PubMed Web of Science ®Google Scholar
• Cibickova L, Radomir H, Stanislav M et al. The influence of simvastatin, atorvastatin and high-cholesterol diet on acetylcholinesterase activity, amyloid β and cholesterol synthesis in rat brain. Steroid.74(1), 13–19 (2009).
   PubMed Web of Science ®Google Scholar
• Kirsch C, Eckert GP, Mueller WE. Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem. Pharmacol.65, 843–856 (2003).
   PubMed Web of Science ®Google Scholar
• Zipp F, Waiczies S, Aktas O et al. Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol. Sci.28(7), 342–349 (2007).
   PubMed Web of Science ®Google Scholar
• Buxbaum JD, Geoghagen NS, Friedhoff LT. Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Aβ peptide. J. Alzheimers Dis.3(2), 221–229 (2001).
   PubMed Web of Science ®Google Scholar
• Park IH, Hwang EM, Hong HS et al. Lovastatin enhances Aβ production and senile plaque deposition in female Tg2576 mice. Neurobiol. Aging24(5), 637–643 (2003).
   PubMed Web of Science ®Google Scholar
• Parsons RB, Farrant JK, Price GC, Subramaniam D, Austen BM. Regulation of the lipidation of β-secretase by statins. Biochem. Soc. Trans.35(Pt 3), 577–582 (2007).
   PubMed Web of Science ®Google Scholar
• Ostrowski SM, Wilkinson BL, Golde TE, Landreth G. Statins reduce amyloid-β production through inhibition of protein isoprenylation. J. Biol. Chem.282(37), 26832–26844 (2007).
   PubMed Web of Science ®Google Scholar
• Reid PC, Urano Y, Kodama T, Hamakubo T. Alzheimer’s disease: cholesterol, membrane rafts, isoprenoids and statins. J. Cell. Mol. Med.11(3), 383–392 (2007).
   PubMed Web of Science ®Google Scholar
• Cordle A, Landreth G. 3-Hydroxy-3-methylglutarylcoenzyme A reductase inhibitors attenuate β-amyloid-induced microglial inflammatory responses. J. Neurosci.25, 299–307 (2005).
   PubMed Web of Science ®Google Scholar
• Li L, Cao D, Kim H, Lester R, Fukuchi K. Simvastatin enhances learning and memory independent of amyloid load in mice. Ann. Neurol.60(6), 729–739 (2006).
   PubMed Web of Science ®Google Scholar
• Höglund K, Blennow K. Effect of HMG-CoA reductase inhibitors on β-amyloid peptide levels: implications for Alzheimer’s disease. CNS Drugs21(6), 449–462 (2007).
   PubMed Web of Science ®Google Scholar
• Jick H, Zornberg GL, Jick SS et al. Statins and the risk of dementia. Lancet356, 1627–1631 (2000).
   PubMed Web of Science ®Google Scholar
• Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol.59, 223–227 (2002).
   PubMed Web of Science ®Google Scholar
• Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer’s disease. Neuroepidemiology23, 94–98 (2004).
   PubMed Web of Science ®Google Scholar
• Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch. Neurol.61(5), 705–714 (2004).
   PubMed Web of Science ®Google Scholar
• Li G, Higdon R, Kukull WA et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology63, 1624–1628 (2004).
   PubMed Web of Science ®Google Scholar
• Zandi PP, Sparks DL, Khachaturian AS et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch. Gen. Psychiatry62, 217–224 (2005).
   PubMed Web of Science ®Google Scholar
• Rea TD, Breitner JC, Psaty BM et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch. Neurol.62, 1047–1051 (2005).
   PubMed Web of Science ®Google Scholar
• Li G, Kukull W, Peskind E et al. Differential effect of statins on risk of AD by age, sex, and APOE genotype: findings from a community-based prospective cohort study. Alzheimer Dis. Assoc. Disord.20(Suppl. 2), S103–S104 (2006).
   Google Scholar
• Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med.5, 20 (2007).
   PubMed Web of Science ®Google Scholar
• Arvanitakis Z, Schneider JA, Wilson RS et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology70(19 Pt 2), 1795–1802 (2008).
   PubMed Web of Science ®Google Scholar
• Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br. J. Clin. Pharmacol.67(1), 99–109 (2009).
   PubMed Web of Science ®Google Scholar
• Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry80(1), 13–17 (2009).
   PubMed Web of Science ®Google Scholar
• Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr. Alzheimer Res.5(4), 416–421 (2008).
   PubMed Web of Science ®Google Scholar
• Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch. Neurol.59(3), 378–384 (2002).
   PubMed Web of Science ®Google Scholar
• Bernick C, Katz R, Smith NL et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology65(9), 1388–1394 (2005).
   PubMed Web of Science ®Google Scholar
• Parale GP, Baheti NN, Kulkarni PM, Panchal NV. Effects of atorvastatin on higher functions. Eur. J. Clin. Pharmacol.62(4), 259–265 (2006).
   PubMed Web of Science ®Google Scholar
• Li G, Larson EB, Sonnen JA et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology69(9), 878–885 (2007).
   PubMed Web of Science ®Google Scholar
• Solomon A, Kåreholt I, Ngandu T et al. Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol. Aging (2007) (Epub ahead of print).
   Google Scholar
• Rockwood K, Howlett S, Fisk J et al. Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status. Neuroepidemiology29(3–4), 201–207 (2007).
   PubMed Web of Science ®Google Scholar
• Szwast SJ, Hendrie HC, Lane KA et al. Association of statin use with cognitive decline in elderly African Americans. Neurology69(19), 1873–1880 (2007).
   PubMed Web of Science ®Google Scholar
• Reitz C, Tang MX, Manly J, Schupf N, Mayeux R, Luchsinger JA. Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement. Geriatr. Cogn. Disord.25(3), 232–237 (2008).
   PubMed Web of Science ®Google Scholar
• Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology71(5), 344–350 (2008).
   PubMed Web of Science ®Google Scholar
• Muldoon MF, Barger SD, Ryan CM et al. Effects of lovastatin on cognitive function and psychological well-being. Am. J. Med.108(7), 538–546 (2000).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360(9326), 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet360(9346), 1623–1630 (2002).
   PubMed Web of Science ®Google Scholar
• Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am. J. Med.117(11), 823–829 (2004).
   PubMed Web of Science ®Google Scholar
• Carlsson CM, Gleason CE, Hess TM et al. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer’s disease. J. Alzheimers Dis.13(2), 187–197 (2008).
   PubMed Web of Science ®Google Scholar
• Rockwood K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer’s disease. Acta Neurol. Scand. Suppl.185, 71–77 (2006).
   PubMedGoogle Scholar
• Moroney JT, Tseng CL, Paik MC, Mohr JP, Desmond DW. Treatment for the secondary prevention of stroke in older patients: the influence of dementia status. J. Am. Geriatr. Soc.47, 824–829 (1999).
   PubMed Web of Science ®Google Scholar
• McKenney JM, Davidson MH, Jacobson TA, Guyton JR; National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am. J. Cardiol.97(8A), 89C–94C (2006).
   PubMed Web of Science ®Google Scholar
• Simons M, Schwärzler F, Lütjohann D et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol.52(3), 346–350 (2002).
   PubMed Web of Science ®Google Scholar
• Sparks DL, Sabbagh MN, Connor DJ et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol.62(5), 753–757 (2005).
   PubMed Web of Science ®Google Scholar
• Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer’s disease: results of the Alzheimer’s Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol. Scand. Suppl.185, 3–7 (2006).
   PubMedGoogle Scholar
• Sparks DL, Lemieux SK, Haut MW et al. Hippocampal volume change in the Alzheimer disease cholesterol-lowering treatment trial. Cleve. Clin. J. Med.75(Suppl. 2), S87–S93 (2008).
   PubMedGoogle Scholar
• Fox NC, Black RS, Gilman S et al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology64, 1563–1572 (2005).
   PubMed Web of Science ®Google Scholar
• Jones RW, Kivipelto M, Feldman H et al. The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement.4(2), 145–153 (2008).
   PubMed Web of Science ®Google Scholar
• Sparks L. Statins and cognitive function. J. Neurol. Neurosurg. Psychiatry80(1), 1–2 (2009).
   PubMed Web of Science ®Google Scholar
• Sparks DL, Kivipelto M, Doody R et al. The Atorvastatin/Donepezil in Alzheimer’s Disease (LEADe) study: effect of atorvastatin on Alzheimer’s disease progression by ApoE4 genotype. Presented at: Alzheimer’s Association International Conference on Alzheimer’s Disease. Chicago, IL, USA, 26–31 July 2008 (Abstract).
   Google Scholar
• Sano M. Multi-center, randomized, double-blind, placebo-controlled trial of Simvastatin to slow the progression of Alzheimer’s disease. Presented at: Alzheimer’s Association International Conference on Alzheimer’s Disease Chicago, IL, USA, 26–31 July 2008 (Abstract T200).
   Google Scholar
• Masse I, Bordet R, Deplanque D et al. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry76(12), 1624–1629 (2005).
   PubMed Web of Science ®Google Scholar
• Ellul J, Archer N, Foy CM et al. The effects of commonly prescribed drugs in patients with Alzheimer’s disease on the rate of deterioration. J. Neurol. Neurosurg. Psychiatry78(3), 233–239 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenberg PB, Mielke MM, Tschanz J et al. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am. J. Geriatr. Psychiatry16(11), 883–892 (2008).
   PubMed Web of Science ®Google Scholar
• Horsdal HT, Olesen AV, Gasse C, Sørensen HT, Green RC, Johnsen SP. Use of statins and risk of hospitalization with dementia: a Danish population-based case–control study. Alzheimer Dis. Assoc. Disord.23(1), 18–22 (2008).
   Web of Science ®Google Scholar
• Winblad B, Jelic V, Kershaw P, Amatniek J. Effects of statins on cognitive function in patients with Alzheimer’s disease in galantamine clinical trials. Drugs Aging24(1), 57–61 (2007).
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA criteria. Lancet Neurol.6, 734–746 (2007).
   PubMed Web of Science ®Google Scholar
• Erkinjuntti T. Vascular cognitive deterioration and stroke. Cerebrovasc. Dis.24(Suppl. 1), 189–194 (2007).
   PubMedGoogle Scholar
• Aguero-Torres H, Kivipelto M, von Strauss E. Rethinking the dementia diagnoses in a population-based study: what is Alzheimer’s disease and what is vascular dementia? A study from the Kungsholmen Project. Dement. Geriatr. Cogn. Disord.22, 244–249 (2006).
   PubMed Web of Science ®Google Scholar
• Hachinski V. Shifts in thinking about dementia. JAMA300(18), 2172–2173 (2008).
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Rovio S, Ngandu T et al. Apolipoprotein E ε4 magnifies lifestyle risks for dementia: a population based study. J. Cell. Mol. Med.12, 2762–2771 (2008).
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol.5(9), 735–741 (2006).
   PubMed Web of Science ®Google Scholar